SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study
These findings provide genetic support that SGLT2 inhibition increases osteoporosis risk despite raising BMD. Total testosterone does not appear to mediate this relationship, suggesting other pathways or direct skeletal effects drive the observed bone fragility. Further studies are needed to delineate these mechanisms.
Authors
- Zhong Cao
- Ziyang Cheng (ORCID: https://orcid.org/0000-0002-4498-2443)
- Zhichao Li (ORCID: https://orcid.org/0000-0001-6803-6876)
- Wenbo Wang (ORCID: https://orcid.org/0000-0003-4507-1761)
- Yi Li (ORCID: https://orcid.org/0000-0003-1658-404X)
- Yaxin Chen (ORCID: https://orcid.org/0000-0002-9515-1543)
- Fengyi Zhang
- Jing Luo (ORCID: https://orcid.org/0009-0004-9445-1896)
- Yibing Chen (ORCID: https://orcid.org/0000-0003-0025-7474)
- Yufeng Zhang (ORCID: https://orcid.org/0009-0009-3418-0381)
- Xin Wang
- J. Zhang (ORCID: https://orcid.org/0009-0009-4119-3922)
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Experimental Gerontology
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1016/j.exger.2025.112935
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29